Real-World Safety Analysis of Oral Semaglutide Reveals Expected and Unexpected Side Effects
Analysis of 2,398 FDA adverse event reports for oral semaglutide tablets identified 93 significant safety signals, with gastrointestinal issues dominant and unexpected findings including thyroid cysts, acute cholecystitis, and abducens nerve paralysis.
Quick Facts
What This Study Found
From 2,398 FAERS reports (5,653 adverse events), 23 system organ classes and 93 preferred terms showed significant signals for oral semaglutide, with metabolism/nutrition disorders most signaled and unexpected findings of acute cholecystitis, abducens nerve paralysis, and positional vertigo.
Key Numbers
FAERS data covering 2019-2023 (4 years of post-marketing surveillance). GI events most frequently reported.
How They Did This
Retrospective analysis of FDA FAERS database (Q3 2019 to Q3 2023) for oral semaglutide. Data mining using four signal quantification methods: ROR, PRR, BCPNN, and MGPS for cross-validation.
Why This Research Matters
As oral semaglutide becomes widely prescribed for diabetes and weight management, understanding its real-world safety profile beyond clinical trials is critical. The identification of unexpected adverse events like nerve paralysis and acute cholecystitis informs prescribers and patients.
The Bigger Picture
The GLP-1 drug class is being prescribed to tens of millions of people for diabetes and weight loss. Post-marketing surveillance like this FAERS analysis is essential for detecting rare side effects that clinical trials (typically enrolling thousands) might miss. The gallbladder and neurological signals align with emerging safety concerns across the GLP-1 class.
What This Study Doesn't Tell Us
FAERS is a voluntary reporting system subject to reporting bias — not all adverse events are reported, and reports don't prove causation. The oral formulation's adverse event profile may partly reflect the unique absorption enhancer (SNAC) rather than semaglutide itself. Reporting rates are influenced by media attention and awareness.
Questions This Raises
- ?Is the abducens nerve paralysis signal specific to oral semaglutide or shared with injectable forms?
- ?Does the oral formulation's absorption enhancer (SNAC) contribute to any of the observed GI adverse events?
- ?How do the safety signals change as the total number of users increases over time?
Trust & Context
- Key Stat:
- 93 safety signals Identified from 2,398 real-world FAERS reports for oral semaglutide tablets, including several unexpected adverse events
- Evidence Grade:
- Moderate evidence from a systematic analysis of the FDA's adverse event reporting database using four validated signal detection methods. FAERS data has inherent limitations including voluntary reporting and inability to establish causation.
- Study Age:
- Published in 2024, covering FAERS data from Q3 2019 (oral semaglutide approval) through Q3 2023.
- Original Title:
- Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(8), 1717-1733 (2024)
- Authors:
- Xiong, Si, Gou, Ruoyu, Liang, Xudong, Wu, Hao, Qin, Shuitao, Li, Bing, Luo, Changjun, Chen, Junan
- Database ID:
- RPEP-09563
Evidence Hierarchy
Frequently Asked Questions
Are the side effects of oral semaglutide different from the injectable version?
The most common side effects (nausea, GI issues) are similar. However, this analysis identified some signals — like abducens nerve paralysis — that need further investigation to determine if they're specific to the oral formulation or shared with injectable semaglutide.
Should I be worried about these side effects?
Most reported adverse events are known GI side effects that are typically manageable. The unexpected findings (cholecystitis, nerve paralysis) are rare but worth being aware of. If you experience sudden abdominal pain, jaundice, or double vision while taking oral semaglutide, contact your healthcare provider immediately.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09563APA
Xiong, Si; Gou, Ruoyu; Liang, Xudong; Wu, Hao; Qin, Shuitao; Li, Bing; Luo, Changjun; Chen, Junan. (2024). Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(8), 1717-1733. https://doi.org/10.1007/s13300-024-01594-7
MLA
Xiong, Si, et al. "Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.." Diabetes therapy : research, 2024. https://doi.org/10.1007/s13300-024-01594-7
RethinkPeptides
RethinkPeptides Research Database. "Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide T..." RPEP-09563. Retrieved from https://rethinkpeptides.com/research/xiong-2024-adverse-events-of-oral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.